Summary

The liquid biopsy in cancer diagnostic market is expected to grow at a strong CAGR of around 15% during the forecast period owing to the surge in the incidence of cancers, rising research and development activities for the development of novel liquid biopsy in cancer diagnostic, and the development of a novel pipeline of cancer drugs. Moreover, the rapid launch of new products in the market is also driving the growth of the market during the forecast period. For instance, in August 2020, U.S. FDA granted approval to the first liquid biopsy companion diagnostic test that also uses next-generation sequencing (NGS) technology to identify patients with specific types of mutations of the epidermal growth factor receptor (EGFR) gene in a deadly form of metastatic non-small cell lung cancer (NSCLC). This is the first approval to combine two technologies — NGS and liquid biopsy — in one diagnostic test in order to guide treatment decisions. Thus, these aforementioned factors are driving the market growth during the forecast period.

Some of the major players operating in the market include Myriad Genetics Inc, Exact Sciences Corporation, Biocartis, Sysmex Corporation, Thermo Fisher Scientific Inc, Agilent Technologies Inc, Biocept Inc, MDx Health, Illumina Inc, and QIAGEN. Several M&As along with partnerships have been undertaken by these players to facilitate customers with hi-tech and innovative products/technologies.

Insights Presented in the Report
“Amongst sample, the blood segment held a significant share of the market in 2021”
Based on sample, the market is categorized into blood, urine, and saliva. The blood category held dominant share of the market in 2021. The blood test offers several characteristics such as non-invasiveness, painlessness, cost-effectiveness, and no risk. The circulating biomarkers in the blood have a critical role in understanding tumorigenesis and metastasis, which further can help determine tumor dynamics at the time of treatment and disease progression. In addition, ongoing research on blood-based tests for cancer is expected to drive the market. For instance, in August 2021, a research group at Exact Sciences and UW-Madison started working on liquid biopsies for cancer, including a blood test that helps detect genetic mutations in tumors targeted by drugs. This test can detect recurrence of cancer after treatment as well as help in the early detection of the disease.

“Amongst cancer, the breast cancer category to grow with high CAGR during the forecast period”
By cancer, the market is segmented into lung cancer, breast cancer, colorectal cancer, prostate cancer, and others. The breast cancer segment is anticipated to grow with a significant CAGR during the forecast period due to a significant rise in the prevalence of breast cancer. According to Globocan, in 2020, about 2,261,419 new breast cancer cases were reported worldwide, contributing to about 11.7% of the total cancer cases. In addition to this, rising research activities by scientists for the detection of breast cancer are also having a positive impact on the market growth. For instance, in September 2022, scientists designed special blood draw liquid biopsy test that could determine whether a patient has breast cancer at its early stage and if that cancer is unlikely to return.

“Amongst technique, the next generation sequencing segment held a dominant share of the market in 2021”
Based on technique, the market is bifurcated into polymerase chain reaction and next-generation sequencing. The next generation sequencing held a dominant share of the market in 2021 owing to its capability to detect several mutations which are critical for the development of cancer and for the detection of resistance mechanisms that might have developed from the pre-existing clones after treatment. Moreover, payers in the market have introduced enhanced products which is also propelling the market growth. For instance, in February 2021, Twist Bioscience Corp. launched Twist NGS Methylation Detection System for liquid biopsy cancer analysis and epigenetic studies. In addition, in April 2021, Biodesix, Inc. declared its plan to launch a blood-based 52-gene NGS test to enhance its portfolio of molecular testing.
 
“APAC to grow with high CAGR during the forecast period”
APAC is expected to grow with the highest CAGR during the forecast period due to rising disposable income, the surge in the prevalence of cancer, rising research and development activities, and increasing awareness among individuals. For instance, in September 2021, Chinese startup AnchorDx, together with renowned experts from a top-tier hospital in China, has developed a diagnostic model for early breast cancer detection, based on circulating cell-free DNA-based (cfDNA) methylation patterns. It can serve as a reliable approach for the early diagnosis of breast cancer and is expected to compensate for the deficiency of mammography. Apart from this, regulatory bodies in Japan are also granting approval to these tests, which is also driving the market growth during the forecast period. For instance, in March 2022, the Ministry of Health, Labour and Welfare (MHLW) in Japan has granted regulatory approval of Guardant360 CDx, a liquid biopsy test for tumor mutation profiling, also known as comprehensive genomic profiling (CGP), in patients with advanced solid cancers.

Reasons to buy this report:
• The study includes market sizing and forecasting analysis validated by authenticated key industry experts.
• The report presents a quick review of overall industry performance at one glance.
• The report covers an in-depth analysis of prominent industry peers with a primary focus on key business financials, product portfolios, expansion strategies, and recent developments.
• Detailed examination of drivers, restraints, key trends, and opportunities prevailing in the industry.
• The study comprehensively covers the market across different segments.
• Deep dive regional level analysis of the industry.

Customization Options:
The global liquid biopsy in cancer diagnostic market can further be customized as per the requirement or any other market segment. Besides this, UMI understands that you may have your own business needs, hence feel free to connect with us to get a report that completely suits your requirements.

ページTOPに戻る

Table of Contents

1 MARKET INTRODUCTION
1.1. Market Definitions
1.2. Main Objective
1.3. Stakeholders
1.4. Limitation
2 RESEARCH METHODOLOGY OR ASSUMPTION
2.1. Research Process of the Liquid Biopsy in Cancer Diagnostics Market
2.2. Research Methodology of the Liquid Biopsy in Cancer Diagnostics Market
2.3. Respondent Profile
3 MARKET SYNOPSIS
4 EXECUTIVE SUMMARY
5 IMPACT OF COVID-19 ON THE LIQUID BIOPSY IN CANCER DIAGNOSTICS MARKET
6 LIQUID BIOPSY IN CANCER DIAGNOSTICS MARKET REVENUE (USD BN), 2020-2028F
7 MARKET INSIGHTS BY PRODUCT
7.1. Instruments
7.2. Reagents & Kits
8 MARKET INSIGHTS BY SAMPLE
8.1. Blood
8.2. Urine
8.3. Saliva
9 MARKET INSIGHTS BY CANCER
9.1. Lung Cancer
9.2. Breast Cancer
9.3. Colorectal Cancer
9.4. Prostate Cancer
9.5. Others
10 MARKET INSIGHTS BY BIOMARKER
10.1. Circulating Tumor Cells
10.2. Circulating Tumor DNA
10.3. Circulating Free DNA
10.4. Others
11 MARKET INSIGHTS BY TECHNIQUE
11.1. Polymerase Chain Reaction
11.2. Next Generation Sequencing
12 MARKET INSIGHTS BY REGION
12.1. North America
12.1.1. U.S.
12.1.2. Canada
12.1.3. Rest of North America
12.2. Europe
12.2.1. Germany
12.2.2. U.K.
12.2.3. France
12.2.4. Italy
12.2.5. Spain
12.2.6. Rest of Europe
12.3. Asia-Pacific
12.3.1. China
12.3.2. Japan
12.3.3. India
12.3.4. Rest of Asia-Pacific
12.4. Rest of World
13 LIQUID BIOPSY IN CANCER DIAGNOSTICS MARKET DYNAMICS
13.1. Market Drivers
13.2. Market Challenges
14 LIQUID BIOPSY IN CANCER DIAGNOSTICS MARKET OPPORTUNITIES
15 LIQUID BIOPSY IN CANCER DIAGNOSTICS MARKET TRENDS
16 DEMAND AND SUPPLY-SIDE ANALYSIS
16.1. Demand Side Analysis
16.2. Supply Side Analysis
17 VALUE CHAIN ANALYSIS
18 COMPETITIVE SCENARIO
18.1. Competitive Landscape
18.1.1. Porters Fiver Forces Analysis
19 COMPANY PROFILED
19.1. Myriad Genetics Inc
19.2. Exact Sciences Corporation
19.3. Biocartis
19.4. Sysmex Corporation
19.5. Thermo Fisher Scientific Inc
19.6. Agilent Technologies Inc
19.7. Biocept Inc
19.8. MDx Health
19.9. Illumina Inc
19.10. QIAGEN
20 DISCLAIMER